To view more documents, please visit http://www.snl.com:81/irweblinkx/docs.aspx?IID=109084.
Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW, Ellis IO (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116(3): 340–3450.
Alberghina L, Gaglio D (2014) Redox control of glutamine utilization in cancer. Cell death & disease 5: e1561.
Benassi B, Fanciulli M, Fiorentino F, Porrello A, Chiorino G, Loda M, Zupi G, Biroccio A (2006) c-Myc phosphorylation is required for cellular response to oxidative stress. Mol Cell 21(4): 509–519.
Budczies J, Pfitzner BM, Gyorffy B, Winzer KJ, Radke C, Dietel M, Fiehn O, Denkert C (2015) Glutamate enrichment as new diagnostic opportunity in breast cancer. Int J Cancer 136(7): 1619–1628.
Cao MD, Lamichhane S, Lundgren S, Bofin A, Fjosne H, Giskeodegard GF, Bathen TF (2014) Metabolic characterization of triple negative breast cancer. BMC Cancer 14: 941.
Csibi A, Fendt SM, Li C, Poulogiannis G, Choo AY, Chapski DJ, Jeong SM, Dempsey JM, Parkhitko A, Morrison T, Henske EP, Haigis MC, Cantley LC, Stephanopoulos G, Yu J, Blenis J (2013) The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell 153(4): 840–854.
Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, Group M, Langerod A, Green A, Provenzano E, Wishart G, Pinder S, Watson P, Markowetz F, Murphy L, Ellis I, Purushotham A, Borresen-Dale AL, Brenton JD, Tavare S, Caldas C, Aparicio S (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486(7403): 346–352.
Dang CV (2012) MYC on the path to cancer. Cell 149(1): 22–35.
Ding J, Kuo ML, Su L, Xue L, Luh F, Zhang H, Wang J, Lin TG, Zhang K, Chu P, Zheng S, Liu X, Yen Y (2017) Human mitochondrial pyrroline-5-carboxylate reductase 1 promotes invasiveness and impacts survival in breast cancers. Carcinogenesis 38: 519–531.
Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT, Dang CV (2009) c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458(7239): 762–765.
Green AR, Aleskandarany MA, Agarwal D, Elsheikh S, Nolan CC, Diez-Rodriguez M, Macmillan RD, Ball GR, Caldas C, Madhusudan S, Ellis IO, Rakha EA (2016) MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours. Br J Cancer 114(8): 917–928.
Gross MI, Demo SD, Dennison JB, Chen L, Chernov-Rogan T, Goyal B, Janes JR, Laidig GJ, Lewis ER, Li J, Mackinnon AL, Parlati F, Rodriguez ML, Shwonek PJ, Sjogren EB, Stanton TF, Wang T, Yang J, Zhao F, Bennett MK (2014) Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther 13(4): 890–901.
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5): 646–674.
Hu CA, Khalil S, Zhaorigetu S, Liu Z, Tyler M, Wan G, Valle D (2008) Human Delta1-pyrroline-5-carboxylate synthase: function and regulation. Amino Acids 35(4): 665–672.
Hu W, Zhang C, Wu R, Sun Y, Levine A, Feng Z (2010) Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc Natl Acad Sci USA 107(16): 7455–7460.
Kardos GR, Wastyk HC, Robertson GP (2015) Disruption of proline synthesis in melanoma inhibits protein production mediated by the GCN2 pathway. Mol Cancer Res 13(10): 1408–1420.
Kim S, Kim DH, Jung WH, Koo JS (2013) Expression of glutamine metabolism-related proteins according to molecular subtype of breast cancer. Endocr Relat Cancer 20(3): 339–348.
Krishnan N, Dickman MB, Becker DF (2008) Proline modulates the intracellular redox environment and protects mammalian cells against oxidative stress. Free Radic Biol Med 44(4): 671–681.
Kuo ML, Lee MB, Tang M, den Besten W, Hu S, Sweredoski MJ, Hess S, Chou CM, Changou CA, Su M, Jia W, Su L, Yen Y (2016) PYCR1 and PYCR2 interact and collaborate with RRM2B to protect cells from overt oxidative stress. Sci Rep 6: 18846.
Li B, Simon MC (2013) Molecular pathways: targeting MYC-induced metabolic reprogramming and oncogenic stress in cancer. Clin Cancer Res 19(21): 5835–5841.
Liu W, Hancock CN, Fischer JW, Harman M, Phang JM (2015) Proline biosynthesis augments tumor cell growth and aerobic glycolysis: involvement of pyridine nucleotides. Sci Rep 5: 17206.
Liu W, Le A, Hancock C, Lane AN, Dang CV, Fan TW, Phang JM (2012) Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. Proc Natl Acad Sci USA 109(23): 8983–8988.
Liu W, Phang JM (2012) Proline dehydrogenase (oxidase) in cancer. BioFactors 38(6): 398–406.
Lukey MJ, Greene KS, Erickson JW, Wilson KF, Cerione RA (2016) The oncogenic transcription factor c-Jun regulates glutaminase expression and sensitizes cells to glutaminase-targeted therapy. Nat Commun 7: 11321.
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM Statistics Subcommittee of the NCIEWGoCD (2005) REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 93(4): 387–391.
Natarajan SK, Zhu W, Liang X, Zhang L, Demers AJ, Zimmerman MC, Simpson MA, Becker DF (2012) Proline dehydrogenase is essential for proline protection against hydrogen peroxide induced cell death. Free Radic Biol Med 53(5): 1181–1191.
Phang JM, Liu W, Hancock C (2013) Bridging epigenetics and metabolism: role of non-essential amino acids. Epigenetics 8(3): 231–236.
Phang JM, Liu W, Hancock CN, Fischer JW (2015) Proline metabolism and cancer: emerging links to glutamine and collagen. Curr Opin Clin Nutr Metab Care 18(1): 71–77.
Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B (1997) A model for p53-induced apoptosis. Nature 389(6648): 300–305.
Richardson AD, Yang C, Osterman A, Smith JW (2008) Central carbon metabolism in the progression of mammary carcinoma. Breast Cancer Res Treat 110(2): 297–307.
Soria D, Garibaldi JM, Ambrogi F, Green AR, Powe D, Rakha E, Macmillan RD, Blamey RW, Ball G, Lisboa PJ, Etchells TA, Boracchi P, Biganzoli E, Ellis IO (2010) A methodology to identify consensus classes from clustering algorithms applied to immunohistochemical data from breast cancer patients. Comput Biol Med 40(3): 318–330.
Wang JB, Erickson JW, Fuji R, Ramachandran S, Gao P, Dinavahi R, Wilson KF, Ambrosio AL, Dias SM, Dang CV, Cerione RA (2010) Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer cell 18(3): 207–219.
Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, Nissim I, Daikhin E, Yudkoff M, McMahon SB, Thompson CB (2008) Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA 105(48): 18782–18787.
Wise DR, Thompson CB (2010) Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 35(8): 427–433.
Zeng T, Zhu L, Liao M, Zhuo W, Yang S, Wu W, Wang D (2017) Knockdown of PYCR1 inhibits cell proliferation and colony formation via cell cycle arrest and apoptosis in prostate cancer. Med Oncol 34(2): 27.
Aas T, Borresen AL, Geisler S, SmithSorensen B, Johnsen H, Varhaug JE, Akslen LA, Lonning PE (1996) Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2(7): 811–814.
Abdel Azim S, Sprung S, Mutz-Dehbalaie I, Fessler S, Zeimet AG, Marth C (2017) L1CAM and HER2 expression in early endometrioid uterine cancer. Int J Gynecol Pathol 36(4): 356–363.
Ahmed S, Sami A, Xiang J (2015) HER2-directed therapy: current treatment options for HER2-positive breast cancer. Breast Cancer 22(2): 101–116.
Amir E, Clemons M, Purdie CA, Miller N, Quinlan P, Geddie W, Coleman RE, Freedman OC, Jordan LB, Thompson AM (2012) Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. Cancer Treat Rev 38(6): 708–714.
Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP, Akslen LA (2006) EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 24(2): 268–273.
Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12(4): 395–402.
Black J, Menderes G, Bellone S, Schwab CL, Bonazzoli E, Ferrari F, Predolini F, De Haydu C, Cocco E, Buza N, Hui P, Wong S, Lopez S, Ratner E, Silasi DA, Azodi M, Litkouhi B, Schwartz PE, Goedings P, Beusker PH, van der Lee MM, Timmers CM, Dokter WH, Santin AD (2016) SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows antitumor activity in uterine serous carcinoma with HER2/Neu expression. Mol Cancer Ther 15(8): 1900–1909.
Buza N, English DP, Santin AD, Hui P (2013) Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. Mod Pathol 26(12): 1605–1612.
Buza N, Hui P (2013) Marked heterogeneity of HER2/NEU gene amplification in endometrial serous carcinoma. Genes Chromosomes Cancer 52(12): 1178–1186.
Buza N, Roque DM, Santin AD (2014) HER2/neu in endometrial cancer: a promising therapeutic target with diagnostic challenges. Arch Pathol Lab Med 138(3): 343–350.
Cancer Genome Atlas Research N, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497(7447): 67–73.
Cardoso F, Costa A, Senkus E, Aapro M, Andre F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Pernault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E (2017) 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3). Ann Oncol 28(1): 16–33.
Carvajal-Hausdorf DE, Schalper KA, Bai Y, Black J, Santin AD, Rimm DL (2017) Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance. Gynecol Oncol 145(1): 154–158.
Criscitiello C, Andre F, Thompson AM, De Laurentiis M, Esposito A, Gelao L, Fumagalli L, Locatelli M, Minchella I, Orsi F, Goldhirsch A, Curigliano G (2014) Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives. Breast Cancer Res 16(2): 205.
Diver EJ, Foster R, Rueda BR, Growdon WB (2015) The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer. Oncologist 20(9): 1058–1068.
Dysvik B, Jonassen I (2001) J-Express: exploring gene expression data using Java. Bioinformatics 17(4): 369–370.
Engelsen IB, Stefansson IM, Akslen LA, Salvesen HB (2008a) GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival. Am J Obstet Gynecol 199(5): 543 e1–543 e7.
Engelsen IB, Stefansson IM, Beroukhim R, Sellers WR, Meyerson M, Akslen LA, Salvesen HB (2008b) HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomas. Int J Oncol 32(2): 307–316.
English DP, Roque DM, Santin AD (2013) HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies. Mol Diagn Ther 17(2): 85–99.
Fleming GF (2015) Second-line therapy for endometrial cancer: the need for better options. J Clin Oncol 33(31): 3535–3540.
Fleming GF, Sill MW, Darcy KM, McMeekin DS, Thigpen JT, Adler LM, Berek JS, Chapman JA, DiSilvestro PA, Horowitz IR, Fiorica JV (2010) Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 116(1): 15–20.
Gibson WJ, Hoivik EA, Halle MK, Taylor-Weiner A, Cherniack AD, Berg A, Holst F, Zack TI, Werner HM, Staby KM, Rosenberg M, Stefansson IM, Kusonmano K, Chevalier A, Mauland KK, Trovik J, Krakstad C, Giannakis M, Hodis E, Woie K, Bjorge L, Vintermyr OK, Wala JA, Lawrence MS, Getz G, Carter SL, Beroukhim R, Salvesen HB (2016) The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nat Genet 48(8): 848–855.
Growdon WB, Groeneweg J, Byron V, DiGloria C, Borger DR, Tambouret R, Foster R, Chenna A, Sperinde J, Winslow J, Rueda BR (2015) HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant. Gynecol Oncol 137(1): 160–166.
Hoos A, Urist MJ, Stojadinovic A, Mastorides S, Dudas ME, Leung DH, Kuo D, Brennan MF, Lewis JJ, Cordon-Cardo C (2001) Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol 158(4): 1245–1251.
Jewell E, Secord AA, Brotherton T, Berchuck A (2006) Use of trastuzumab in the treatment of metastatic endometrial cancer. Int J Gynecol Cancer 16(3): 1370–1373.
Jones NL, Xiu J, Chatterjee-Paer S, Buckley de Meritens A, Burke WM, Tergas AI, Wright JD, Hou JY (2017) Distinct molecular landscapes between endometrioid and nonendometrioid uterine carcinomas. Int J Cancer 140(6): 1396–1404.
Jones NL, Xiu J, Reddy SK, Burke WM, Tergas AI, Wright JD, Hou JY (2015) Identification of potential therapeutic targets by molecular profiling of 628 cases of uterine serous carcinoma. Gynecol Oncol 138(3): 620–626.
Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX (2011) Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 128(2): 347–356.
Kataoka Y, Mukohara T, Shimada H, Saijo N, Hirai M, Minami H (2010) Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol 21(2): 255–262.
Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4(7): 844–847.
Krakstad C, Trovik J, Wik E, Engelsen IB, Werner HM, Birkeland E, Raeder MB, Oyan AM, Stefansson IM, Kalland KH, Akslen LA, Salvesen HB (2012) Loss of GPER identifies new targets for therapy among a subgroup of ERalpha-positive endometrial cancer patients with poor outcome. Br J Cancer 106(10): 1682–1688.
Leslie KK, Sill MW, Lankes HA, Fischer EG, Godwin AK, Gray H, Schilder RJ, Walker JL, Tewari K, Hanjani P, Abulafia O, Rose PG (2012) Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecol Oncol 127(2): 345–350.
Lheureux S, Oza AM (2016) Endometrial cancer-targeted therapies myth or reality? Review of current targeted treatments. Eur J Cancer 59: 99–108.
Lin BY, Utleg AG, Gravdal K, White JT, Halvorsen OJ, Lu W, True LD, Vessella R, Lange PH, Nelson PS, Hood L, Kalland KH, Akslen LA (2008) WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence. Clinical Cancer Res 14(5): 1397–1406.
Loibl S, Gianni L (2016) HER2-positive breast cancer. Lancet 389(10087): 2415–2429.
Morrison C, Zanagnolo V, Ramirez N, Cohn DE, Kelbick N, Copeland L, Maxwell GL, Fowler JM (2006) HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol 24(15): 2376–2385.
Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6(2): 117–127.
Niikura N, Liu J, Hayashi N, Mittendorf EA, Gong Y, Palla SL, Tokuda Y, Gonzalez-Angulo AM, Hortobagyi GN, Ueno NT (2012) Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol 30(6): 593–599.
Pandya K, Meeke K, Clementz AG, Rogowski A, Roberts J, Miele L, Albain KS, Osipo C (2011) Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence. Br J Cancer 105(6): 796–806.
Pecorelli S (2009) Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 105(2): 103–104.
Rakha EA, Pinder SE, Bartlett JM, Ibrahim M, Starczynski J, Carder PJ, Provenzano E, Hanby A, Hales S, Lee AH, Ellis IO National Coordinating Committee for Breast P (2015) Updated UK Recommendations for HER2 assessment in breast cancer. J Clin Pathol 68(2): 93–99.
Salvesen HB, Carter SL, Mannelqvist M, Dutt A, Getz G, Stefansson IM, Raeder MB, Sos ML, Engelsen IB, Trovik J, Wik E, Greulich H, Bo TH, Jonassen I, Thomas RK, Zander T, Garraway LA, Oyan AM, Sellers WR, Kalland KH, Meyerson M, Akslen LA, Beroukhim R (2009) Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci USA 106(12): 4834–4839.
Salvesen HB, Haldorsen IS, Trovik J (2012) Markers for individualised therapy in endometrial carcinoma. Lancet Oncol 13(8): e353–e361.
Santin AD (2010) Letter to the Editor referring to the manuscript entitled: “Phase II trial of trastuzumab in women with advanced or recurrent HER-positive endometrial carcinoma: a Gynecologic Oncology Group study” recently reported by Fleming et al., (Gynecol Oncol., 116;15-20;2010). Gynecol Oncol 118(1): 95–96, author reply 96-7.
Santin AD, Bellone S, Buza N, Schwartz PE (2017) Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1). Gynecol Oncol Rep 19: 10–12.
Santin AD, Bellone S, Roman JJ, McKenney JK, Pecorelli S (2008) Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. Int J Gynaecol Obstet 102(2): 128–131.
Santin AD, Bellone S, Van Stedum S, Bushen W, Palmieri M, Siegel ER, De Las Casas LE, Roman JJ, Burnett A, Pecorelli S (2005) Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer 104(7): 1391–1397.
Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM (2007) Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445(7126): 437–441.
Shachar SS, Mashiach T, Fried G, Drumea K, Shafran N, Muss HB, Bar-Sela G (2017) Biopsy of breast cancer metastases: patient characteristics and survival. BMC cancer 17(1): 7.
Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT, Wu W, Sun CC, Munsell MF, Gershenson DM, Lu KH (2004) Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol 22(15): 3126–3132.
Stefansson IM, Salvesen HB, Akslen LA (2004) Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J Clin Oncol 22(7): 1242–1252.
Tangen IL, Werner HM, Berg A, Halle MK, Kusonmano K, Trovik J, Hoivik EA, Mills GB, Krakstad C, Salvesen HB (2014) Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions. Eur J Cancer 50(17): 3003–3010.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2): 87–108.
Vignot S, Besse B, Andre F, Spano JP, Soria JC (2012) Discrepancies between primary tumor and metastasis: a literature review on clinically established biomarkers. Crit Rev Oncol Hematol 84(3): 301–313.
Villella JA, Cohen S, Smith DH, Hibshoosh H, Hershman D (2006) HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. Int J Gynecol Cancer 16(5): 1897–1902.
Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF American Society of Clinical O, College of American P (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31(31): 3997–4013.
Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2): 127–137.
Allen RA, Lisa JR (1949) Combined liver cell and bile duct carcinoma. Am J Pathol 25(4): 647–655.
Bergquist JR, Groeschl RT, Ivanics T, Shubert CR, Habermann EB, Kendrick ML, Farnell MB, Nagorney DM, Truty MJ, Smoot RL (2016) Mixed hepatocellular and cholangiocarcinoma: a rare tumor with a mix of parent phenotypic characteristics. HPB 18: 886–889.
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25–34.
Chok KS, Ng KK, Cheung TT, Yuen WK, Poon RT, Lo CM, Fan ST (2009) An update on long term outcome of curative hepatic resection for hepatocholangiocarcinoma. World J Surg 33: 1916–1921.
Connell LC, Harding JJ, Shia J, Abou-Alfa GK (2016) Combined intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Chin Clin Oncol 5: 66.
Fiteni F, Nguyen T, Vernerey D, Paillard MJ, Kim S, Demarchi M, Fein F, Borg C, Bonnetain F, Pivot X (2014) Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review. Cancer Med 3(6): 1502–1511.
Fowler KJ, Sheybani A, Parker RA 3rd, Doherty S, M Brunt E, Chapman WC, Menias CO (2013) Combined hepatocellular and cholangiocarcinoma (biphenotypic) tumors: imaging features and diagnostic accuracy of contrast enhanced CT and MRI. AJR Am J Roentgenol 201: 332.
Garancini M, Goffredo P, Pagni F, Romano F, Roman S, Sosa JA, Giardini V (2014) Combined hepatocellular-cholangiocarcinoma: a population-level analysis of an uncommon primary liver tumor. Liver Transplant 20: 952–959.
Groeschl RT, Turaga KK, Gamblin TC (2013) Transplantation versus resection for patients with combined hepatocellular carcinomacholangiocarcinoma. J Surg Oncol 107: 608–612.
Jarnagin WR, Weber S, Tickoo SK, Koea JB, Obiekwe S, Fong Y, DeMatteo RP, Blumgart LH, Klimstra D (2002) Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer 94: 2040–2046.
Kim H, Park C, Han KH, Choi J, Kim YB, Kim JK, Park YN (2004) Primary liver carcinoma of intermediate (hepatocyte–cholangiocyte) phenotype. J Hepatol 40: 298–304.
Kim JH, Yoon HK, Ko GY, Gwon DI, Jang CS, Song HY, Shin JH, Sung KB (2010) Nonresectable combined hepatocellular carcinoma and cholangiocarcinoma: analysis of the response and prognostic factors after transcatheter arterial chemoembolization. Radiology 255: 270–277.
Lee WS, Lee KW, Heo JS, Kim SJ, Choi SH, Kim YI, Joh JW (2006) Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Surg Today 36: 892–897.
Li R, Yang D, Tang CL, Cai P, Ma KS, Ding SY, Zhang XH, Guo DY, Yan XC (2016) Combined hepatocellular carcinoma and cholangiocarcinoma (biphenotypic) tumors: clinical characteristics, imaging features of contrast-enhanced ultrasound and computed tomography. BMC Cancer 16: 158.
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J SHARP Investigators Study Group (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4): 378–390.
Maximin S, Ganeshan DM, Shanbhogue AK, Dighe MK, Yeh MM, Kolokythas O, Bhargava P, Lalwani N (2014) Current update on combined hepatocellular- cholangiocarcinoma. Eur J Radiol Open 1: 40–48.
Paik WH, Park YS, Hwang JH, Lee SH, Yoon CJ, Kang SG, Lee JK, Ryu JK, Kim YT, Yoon YB (2009) Palliative treatment with self-expandable metallic stents in patients with advanced type III or IV hilar cholangiocarcinoma: a percutaneous versus endoscopic approach. Gastrointest Endosc 69(1): 55–62.
Panjala C, Senecal DL, Bridges MD, Kim GP, Nakhleh RE, Nguyen JH, Harnois DM (2010) The diagnostic conundrum and liver transplantation outcome for combined hepatocellular-cholangiocarcinoma. Am J Transplant 10: 1263–1267.
Park YH, Hwang S, Ahn CS, Kim KH, Moon DB, Ha TY, Song GW, Jung DH, Park GC, Namgoong JM, Park CS, Park HW, Kang SH, Jung BH, Lee SG (2013) Long-term outcome of liver transplantation for combined hepatocellular carcinoma and cholangiocarcinoma. Transplant Proc 45: 3038–3040.
Piscaglia AC, Shupe TD, Pani G, Tesori V, Gasbarrini A, Petersen BE (2009) Establishment of cancer cell lines from rat hepatocholangiocarcinoma and assessment of the role of granulocyte-colony stimulating factor and hepatocyte growth factor in their growth, motility and survival. J Hepatol 51: 77–92.
Sapisochin G, Fidelman N, Roberts JP, Yao FY (2011) Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma. Liver Transplant 17(8): 934–942.
Tagushi J, Nakashima O, Tanaka M, Hisaka T, Takazawa T, Koijiro M (1996) A clinicopathological study on combined hepatocellular and cholangiocarcinoma. J Gastroenterol Hepatol 11: 758–764.
Tang D, Nagano H, Nakamura M, Wada H, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Dono K, Monden M (2006) Clinical and pathological features of Allen’s type C classification of resected combined hepatocellular and cholangiocarcinoma: a comparative study with hepatocellular carcinoma and cholangiocellular carcinoma. J Gastrointest Surg 10: 987–998.
Theise ND, Nakashima O, Park YN, Nakanuma Y (2010) Combined hepatocellular-cholangiocarcinoma. In: Who classification of tumours of the digestive system FT Bosman, F Carneiro, RH Hruban, ND Theise, (eds) 4th edn. 225–227. IARC: Lyon, France.
Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J ABC-02 Trial Investigators (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362(14): 1273–1281.
Vienne A, Hobeika E, Gouya H, Lapidus N, Fritsch J, Choury AD, Chryssostalis A, Gaudric M, Pelletier G, Buffet C, Chaussade S, Prat F (2010) Prediction of drainage effectiveness during endoscopic stenting of malignant hilar strictures: the role of liver volume assessment. Gastrointest Endosc 72(4): 728–735.
Vilchez V, Shah MB, Daily MF, Pena L, Tzeng CW, Davenport D, Hosein PJ, Gedaly R, Maynard E (2016) Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: an analysis of the UNOS database. HPB 18: 29–34.
Wachtel MS, Zhang Y, Xu T, Chiriva-Internati M, Frezza EE (2008) Combined hepatocellular cholangiocarcinomas; analysis of a large database. Clin Med Pathol 1: 43–47.
Wang J, Wang F, Kessinger A (2010) Outcome of combined hepatocellular and cholangiocarcinoma of the liver. J Oncol 1–7.
Zaanan A, Williet N, Hebbar M, Dabakuyo TS, Fartoux L, Mansourbakht T, Dubreuil O, Rosmorduc O, Cattan S, Bonnetain F, Boige V, Taïeb J (2013) Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study. J Hepatol 58(1): 81–88.
Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K, Sheehan S, Hale KE, Enzinger PC, Bhargava P, Stuart K (2006) Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 24(12): 1898–1903.
Zhu AX, Meyerhardt JA, Blaszkowsky LS, Kambadakone AR, Muzikansky A, Zheng H, Clark JW, Abrams TA, Chan JA, Enzinger PC, Bhargava P, Kwak EL, Allen JN, Jain SR, Stuart K, Horgan K, Sheehan S, Fuchs CS, Ryan DP, Sahani DV (2010) Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol 11(1): 48–54.
Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L (2003) ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res 63(7): 1684–1695.
Ahmed OI, Adel AM, Diab DR, Gobran NS (2006) Prognostic value of serum level of interleukin-6 and interleukin-8 in metastatic breast cancer patients. Egypt J Immunol 13(2): 61–68.
Caliari SR, Perepelyuk M, Soulas EM, Lee GY, Wells RG, Burdick JA (2016) Gradually softening hydrogels for modeling hepatic stellate cell behavior during fibrosis regression. Integr Biol (Camb) 8(6): 720–728.
Chao Y, Wu Q, Shepard C, Wells A (2012) Hepatocyte induced re-expression of E-cadherin in breast and prostate cancer cells increases chemoresistance. Clin Exp Metastasis 29(1): 39–50.
Chao YL, Shepard CR, Wells A (2010) Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol Cancer 9(1): 179.
Clark AM, Wheeler SE, Young CL, Stockdale L, Shepard Neiman J, Zhao W, Stolz DB, Venkataramanan R, Lauffenburger D, Griffith L, Wells A (2017) A liver microphysiological system of tumor cell dormancy and inflammatory responsiveness is affected by scaffold properties. Lab Chip 17(1): 156–168.
ClinicalTrials.gov [Internet] (2015a) A Double-blind Study of Paclitaxel in Combination with Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer (FRIDA). National Library of Medicine (US): Bethesda, MD.
ClinicalTrials.gov [Internet] (2015b) HuMax-IL8 (Interleukin8) in Patients with Advanced Malignant Solid Tumors. National Library of Medicine (US): Bethesda, MD.
Coulouarn C, Corlu A, Glaise D, Guenon I, Thorgeirsson SS, Clement B (2012) Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma. Cancer Res 72(10): 2533–2542.
Derin D, Soydinc HO, Guney N, Tas F, Camlica H, Duranyildiz D, Yasasever V, Topuz E (2007) Serum IL-8 and IL-12 levels in breast cancer. Med Oncol 24(2): 163–168.
Dingal PC, Bradshaw AM, Cho S, Raab M, Buxboim A, Swift J, Discher DE (2015) Fractal heterogeneity in minimal matrix models of scars modulates stiff-niche stem-cell responses via nuclear exit of a mechanorepressor. Nat Mater 14(9): 951–960.
Fang WB, Jokar I, Zou A, Lambert D, Dendukuri P, Cheng N (2012) CCL2/CCR2 chemokine signaling coordinates survival and motility of breast cancer cells through Smad3 protein- and p42/44 mitogen-activated protein kinase (MAPK)-dependent mechanisms. J Biol Chem 287(43): 36593–36608.
Fernando RI, Castillo MD, Litzinger M, Hamilton DH, Palena C (2011) IL-8 signaling plays a critical role in the epithelial–mesenchymal transition of human carcinoma cells. Cancer Res 71(15): 5296–5306.
Freund A, Chauveau C, Brouillet JP, Lucas A, Lacroix M, Licznar A, Vignon F, Lazennec G (2003) IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells. Oncogene 22(2): 256–265.
Friedman SL (2008) Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 88(1): 125–172.
Fujita T, Soontrapa K, Ito Y, Iwaisako K, Moniaga CS, Asagiri M, Majima M, Narumiya S (2016) Hepatic stellate cells relay inflammation signaling from sinusoids to parenchyma in mouse models of immune-mediated hepatitis. Hepatology 63(4): 1325–1339.
Ghajar CM, Peinado H, Mori H, Matei IR, Evason KJ, Brazier H, Almeida D, Koller A, Hajjar KA, Stainier DY, Chen EI, Lyden D, Bissell MJ (2013) The perivascular niche regulates breast tumour dormancy. Nat Cell Biol 15(7): 807–817.
Goswami CP, Nakshatri H (2013) PROGgene: gene expression based survival analysis web application for multiple cancers. J Clin Bioinform 3(1): 22.
Hirose K, Hakozaki M, Nyunoya Y, Kobayashi Y, Matsushita K, Takenouchi T, Mikata A, Mukaida N, Matsushima K (1995) Chemokine gene transfection into tumour cells reduced tumorigenicity in nude mice in association with neutrophilic infiltration. Br J Cancer 72(3): 708–714.
Holliday DL, Speirs V (2011) Choosing the right cell line for breast cancer research. Breast Cancer Res 13(4): 215.
Jiang F, Parsons CJ, Stefanovic B (2006) Gene expression profile of quiescent and activated rat hepatic stellate cells implicates Wnt signaling pathway in activation. J Hepatol 45(3): 401–409.
Karrison TG, Ferguson DJ, Meier P (1999) Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst 91(1): 80–85.
Lee LF, Hellendall RP, Wang Y, Haskill JS, Mukaida N, Matsushima K, Ting JP (2000) IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration. J Immunol 164(5): 2769–2775.
Lee Y-TM (1985) Patterns of metastasis and natural courses of breast carcinoma. Cancer Metastasis Rev 4: 153–172.
Lee YS, Choi I, Ning Y, Kim NY, Khatchadourian V, Yang D, Chung HK, Choi D, LaBonte MJ, Ladner RD, Nagulapalli Venkata KC, Rosenberg DO, Petasis NA, Lenz HJ, Hong YK (2012) Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis. Br J Cancer 106(11): 1833–1841.
Luppi F, Longo AM, de Boer WI, Rabe KF, Hiemstra PS (2007) Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation. Lung Cancer 56(1): 25–33.
Ma B, Wheeler SE, Clark AM, Whaley DL, Yang M, Wells A (2016) Liver protects metastatic prostate cancer from induced death by activating E-cadherin signaling. Hepatology 64(5): 1725–1742.
Ma Y, Ren Y, Dai ZJ, Wu CJ, Ji YH, Xu J (2017) IL-6, IL-8 and TNF-alpha levels correlate with disease stage in breast cancer patients. Adv Clin Exp Med 26(3): 421–426.
MacManus CF, Pettigrew J, Seaton A, Wilson C, Maxwell PJ, Berlingeri S, Purcell C, McGurk M, Johnston PG, Waugh DJ (2007) Interleukin-8 signaling promotes translational regulation of cyclin D in androgen-independent prostate cancer cells. Mol Cancer Res 5(7): 737–748.
Magnus N, Garnier D, Meehan B, McGraw S, Lee TH, Caron M, Bourque G, Milsom C, Jabado N, Trasler J, Pawlinski R, Mackman N, Rak J (2014) Tissue factor expression provokes escape from tumor dormancy and leads to genomic alterations. Proc Natl Acad Sci USA 111(9): 3544–3549.
McCloy RA, Rogers S, Caldon CE, Lorca T, Castro A, Burgess A (2014) Partial inhibition of Cdk1 in G 2 phase overrides the SAC and decouples mitotic events. Cell Cycle 13(9): 1400–1412.
Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW (2011) CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475(7355): 222–225.
Roca H, Varsos ZS, Sud S, Craig MJ, Ying C, Pienta KJ (2009) CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. J Biol Chem 284(49): 34342–34354.
Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M, Ceccarelli C, Santini D, Paterini P, Marcu KB, Chieco P, Bonafe M (2007) IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 117(12): 3988–4002.
Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1): 7–30.
Swift J, Ivanovska IL, Buxboim A, Harada T, Dingal PC, Pinter J, Pajerowski JD, Spinler KR, Shin JW, Tewari M, Rehfeldt F, Speicher DW, Discher DE (2013) Nuclear lamin-A scales with tissue stiffness and enhances matrix-directed differentiation. Science 341(6149): 1240104.
Tabariès S, Siegel P (2011) Breast cancer liver metastasis. In Liver Metastasis: Biology and Clinical Management, Brodt P (ed) Vol. 16, Chapter 10, pp 273–306. Springer: NY, USA.
Taylor DP, Clark A, Wheeler S, Wells A (2014) Hepatic nonparenchymal cells drive metastatic breast cancer outgrowth and partial epithelial to mesenchymal transition. Breast Cancer Res Treat 144(3): 551–560.
Taylor DP, Wells JZ, Savol A, Chennubhotla C, Wells A (2013) Modeling boundary conditions for balanced proliferation in metastatic latency. Clin Cancer Res 19(5): 1063–1070.
Wheeler SE, Clark AM, Taylor DP, Young CL, Pillai VC, Stolz DB, Venkataramanan R, Lauffenburger D, Griffith L, Wells A (2014) Spontaneous dormancy of metastatic breast cancer cells in an all human liver microphysiologic system. Br J Cancer 111(12): 2342–2350.
Xu L, Hui AY, Albanis E, Arthur MJ, O’Byrne SM, Blaner WS, Mukherjee P, Friedman SL, Eng FJ (2005) Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 54(1): 142–151.
Yang M, Ma B, Shao H, Clark AM, Wells A (2016) Macrophage phenotypic subtypes diametrically regulate epithelial–mesenchymal plasticity in breast cancer cells. BMC Cancer 16(1): 419.
Yao C, Lin Y, Chua MS, Ye CS, Bi J, Li W, Zhu YF, Wang SM (2007) Interleukin-8 modulates growth and invasiveness of estrogen receptor-negative breast cancer cells. Int J Cancer 121(9): 1949–1957.
Yuan N, Meng M, Liu C, Feng L, Hou L, Ning Q, Xin G, Pei L, Gu S, Li X, Zhao X (2014) Clinical characteristics and prognostic analysis of triple-negative breast cancer patients. Mol Clin Oncol 2(2): 245–251.
Zhao W, Zhang L, Yin Z, Su W, Ren G, Zhou C, You J, Fan J, Wang X (2011) Activated hepatic stellate cells promote hepatocellular carcinoma development in immunocompetent mice. Int J Cancer 129(11): 2651–2661.
Al-Aynati MM, Radulovich N, Riddell RH, Tsao MS (2004) Epithelial-cadherin and beta-catenin expression changes in pancreatic intraepithelial neoplasia. Clin Cancer Res 10(4): 1235–1240.
Bailey P, Chang DK, Nones K, Johns AL, Patch AM, Gingras MC, Miller DK, Christ AN, Bruxner TJ, Quinn MC, Nourse C, Murtaugh LC, Harliwong I, Idrisoglu S, Manning S, Nourbakhsh E, Wani S, Fink L, Holmes O, Chin V, Anderson MJ, Kazakoff S, Leonard C, Newell F, Waddell N, Wood S, Xu Q, Wilson PJ, Cloonan N, Kassahn KS, Taylor D, Quek K, Robertson A, Pantano L, Mincarelli L, Sanchez LN, Evers L, Wu J, Pinese M, Cowley MJ, Jones MD, Colvin EK, Nagrial AM, Humphrey ES, Chantrill LA, Mawson A, Humphris J, Chou A, Pajic M, Scarlett CJ, Pinho AV, Giry-Laterriere M, Rooman I, Samra JS, Kench JG, Lovell JA, Merrett ND, Toon CW, Epari K, Nguyen NQ, Barbour A, Zeps N, Moran-Jones K, Jamieson NB, Graham JS, Duthie F, Oien K, Hair J, Grützmann R, Maitra A, Iacobuzio-Donahue CA, Wolfgang CL, Morgan RA, Lawlor RT, Corbo V, Bassi C, Rusev B, Capelli P, Salvia R, Tortora G, Mukhopadhyay D, Petersen GM, Munzy DM, Fisher WE, Karim SA, Eshleman JR, Hruban RH, Pilarsky C, Morton JP, Sansom OJ, Scarpa A, Musgrove EA, Bailey UM, Hofmann O, Sutherland RL, Wheeler DA, Gill AJ, Gibbs RA, Pearson JV, Biankin AV, Grimmond SM Initiative APCG (2016) Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531(7592): 47–52.
Bauer R, Valletta D, Bauer K, Thasler WE, Hartmann A, Müller M, Reichert TE, Hellerbrand C (2014) Downregulation of P-cadherin expression in hepatocellular carcinoma induces tumourigenicity. Int J Clin Exp Pathol 7(9): 6125–6132.
Castro-Castro A, Marchesin V, Monteiro P, Lodillinsky C, Rossé C, Chavrier P (2016) Cellular and molecular mechanisms of MT1-MMP-dependent cancer cell invasion. Annu Rev Cell Dev Biol 32: 555–576.
Chai MG, Kim-Fuchs C, Angst E, Sloan EK (2013) Bioluminescent orthotopic model of pancreatic cancer progression. J Vis Exp (76).
Cheung LW, Leung PC, Wong AS (2010) Cadherin switching and activation of p120 catenin signaling are mediators of gonadotropin-releasing hormone to promote tumor cell migration and invasion in ovarian cancer. Oncogene 29(16): 2427–2440.
De Wever O, Derycke L, Hendrix A, De Meerleer G, Godeau F, Depypere H, Bracke M (2007) Soluble cadherins as cancer biomarkers. Clin Exp Metastasis 24(8): 685–697.
Duconseil P, Gilabert M, Gayet O, Loncle C, Moutardier V, Turrini O, Calvo E, Ewald J, Giovannini M, Gasmi M, Bories E, Barthet M, Ouaissi M, Goncalves A, Poizat F, Raoul JL, Secq V, Garcia S, Viens P, Iovanna J, Dusetti N (2015) Transcriptomic analysis predicts survival and sensitivity to anticancer drugs of patients with a pancreatic adenocarcinoma. Am J Pathol 185(4): 1022–1032.
Fabre C, el Battari A, Bellan C, Pasqualini E, Marvaldi J, Lombardo D, Luis J (1993) Characterization of the oligosaccharide moiety of VIP receptor from the human pancreatic cell line BxPC-3. Peptides 14(6): 1331–1338.
Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA (2012) The pancreas cancer microenvironment. Clin Cancer Res 18(16): 4266–4276.
Gayet O, Loncle C, Duconseil P, Gilabert M, Lopez MB, Moutardier V, Turrini O, Calvo E, Ewald J, Giovannini M, Gasmi M, Bories E, Barthet M, Ouaissi M, Goncalves A, Poizat F, Raoul JL, Secq V, Garcia S, Viens P, Dusetti N, Iovanna J (2015) A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor. Oncotarget 6(2): 746–754.
Gimona M, Buccione R, Courtneidge SA, Linder S (2008) Assembly and biological role of podosomes and invadopodia. Curr Opin Cell Biol 20(2): 235–241.
Gul IS, Hulpiau P, Saeys Y, van Roy F (2017) Evolution and diversity of cadherins and catenins. Exp Cell Res 358(1): 3–9.
Hruban RH, Maitra A, Schulick R, Laheru D, Herman J, Kern SE, Goggins M (2008) Emerging molecular biology of pancreatic cancer. Gastrointest Cancer Res 2(4 Suppl): S10–S15.
Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, Harao M, Inoue M, Tsunoda T, Nakatsuru S, Nakagawa H, Nakamura Y, Baba H, Nishimura Y (2008) Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers. Clin Cancer Res 14(20): 6487–6495.
Jakubowska K, Pryczynicz A, Januszewska J, Sidorkiewicz I, Kemona A, Niewiński A, Lewczuk Ł, Kędra B, Guzińska-Ustymowicz K (2016) Expressions of matrix metalloproteinases 2, 7, and 9 in carcinogenesis of pancreatic ductal adenocarcinoma. Dis Markers 2016: 9895721.
Karandish F, Mallik S (2016) Biomarkers and Targeted Therapy in Pancreatic Cancer. Biomark Cancer 8(Suppl 1): 27–35.
Kim MP, Evans DB, Wang H, Abbruzzese JL, Fleming JB, Gallick GE (2009) Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc 4(11): 1670–1680.
Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, Neale RE, Tempero M, Tuveson DA, Hruban RH, Neoptolemos JP (2016) Pancreatic cancer. Nat Rev Dis Primers 2: 16022.
Laklai H, Miroshnikova YA, Pickup MW, Collisson EA, Kim GE, Barrett AS, Hill RC, Lakins JN, Schlaepfer DD, Mouw JK, LeBleu VS, Roy N, Novitskiy SV, Johansen JS, Poli V, Kalluri R, Iacobuzio-Donahue CA, Wood LD, Hebrok M, Hansen K, Moses HL, Weaver VM (2016) Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Nat Med 22(5): 497–505.
Leca J, Martinez S, Lac S, Nigri J, Secq V, Rubis M, Bressy C, Sergé A, Lavaut MN, Dusetti N, Loncle C, Roques J, Pietrasz D, Bousquet C, Garcia S, Granjeaud S, Ouaissi M, Bachet JB, Brun C, Iovanna JL, Zimmermann P, Vasseur S, Tomasini R (2016) Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness. J Clin Invest 126(11): 4140–4156.
Nakajima S, Doi R, Toyoda E, Tsuji S, Wada M, Koizumi M, Tulachan SS, Ito D, Kami K, Mori T, Kawaguchi Y, Fujimoto K, Hosotani R, Imamura M (2004) N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clin Cancer Res 10(12 Pt 1): 4125–4133.
Nelson WJ (2008) Regulation of cell–cell adhesion by the cadherin-catenin complex. Biochem Soc Trans 36(Pt 2): 149–155.
Niessen CM, Leckband D, Yap AS (2011) Tissue organization by cadherin adhesion molecules: dynamic molecular and cellular mechanisms of morphogenetic regulation. Physiol Rev 91(2): 691–731.
Ottaviano AJ, Sun L, Ananthanarayanan V, Munshi HG (2006) Extracellular matrix-mediated membrane-type 1 matrix metalloproteinase expression in pancreatic ductal cells is regulated by transforming growth factor-beta1. Cancer Res 66(14): 7032–7040.
Paredes J, Stove C, Stove V, Milanezi F, Van Marck V, Derycke L, Mareel M, Bracke M, Schmitt F (2004) P-cadherin is up-regulated by the antiestrogen ICI 182,780 and promotes invasion of human breast cancer cells. Cancer Res 64(22): 8309–8317.
Plutoni C, Bazellieres E, Le Borgne-Rochet M, Comunale F, Brugues A, Séveno M, Planchon D, Thuault S, Morin N, Bodin S, Trepat X, Gauthier-Rouvière C (2016) P-cadherin promotes collective cell migration via a Cdc42-mediated increase in mechanical forces. J Cell Biol 212(2): 199–217.
Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM (2014) Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74(11): 2913–2921.
Ribeiro AS, Albergaria A, Sousa B, Correia AL, Bracke M, Seruca R, Schmitt FC, Paredes J (2010) Extracellular cleavage and shedding of P-cadherin: a mechanism underlying the invasive behaviour of breast cancer cells. Oncogene 29(3): 392–402.
Ribeiro AS, Paredes J (2014) P-cadherin linking breast cancer stem cells and invasion: a promising marker to identify an ‘intermediate/metastable’ EMT state. Front Oncol 4: 371.
Ribeiro AS, Sousa B, Carreto L, Mendes N, Nobre AR, Ricardo S, Albergaria A, Cameselle-Teijeiro JF, Gerhard R, Söderberg O, Seruca R, Santos MA, Schmitt F, Paredes J (2013) P-cadherin functional role is dependent on E-cadherin cellular context: a proof of concept using the breast cancer model. J Pathol 229(5): 705–718.
Rodriguez FJ, Lewis-Tuffin LJ, Anastasiadis PZ (2012) E-cadherin’s dark side: possible role in tumor progression. Biochim Biophys Acta 1826(1): 23–31.
Sakamoto K, Imai K, Higashi T, Taki K, Nakagawa S, Okabe H, Nitta H, Hayashi H, Chikamoto A, Ishiko T, Beppu T, Baba H (2015) Significance of P-cadherin overexpression and possible mechanism of its regulation in intrahepatic cholangiocarcinoma and pancreatic cancer. Cancer Sci 106(9): 1153–1162.
Singh M, Maitra A (2007) Precursor lesions of pancreatic cancer: molecular pathology and clinical implications. Pancreatology 7(1): 9–19.
Siret C, Terciolo C, Dobric A, Habib MC, Germain S, Bonnier R, Lombardo D, Rigot V, André F (2015) Interplay between cadherins and α2β1 integrin differentially regulates melanoma cell invasion. Br J Cancer 113(10): 1445–1453.
Steffen A, Le Dez G, Poincloux R, Recchi C, Nassoy P, Rottner K, Galli T, Chavrier P (2008) MT1-MMP-dependent invasion is regulated by TI-VAMP/VAMP7. Curr Biol 18(12): 926–931.
Su Y, Li J, Shi C, Hruban RH, Radice GL (2016) N-cadherin functions as a growth suppressor in a model of K-ras-induced PanIN. Oncogene 35(25): 3335–3341.
Taniuchi K, Nakagawa H, Hosokawa M, Nakamura T, Eguchi H, Ohigashi H, Ishikawa O, Katagiri T, Nakamura Y (2005) Overexpressed P-cadherin/CDH3 promotes motility of pancreatic cancer cells by interacting with p120ctn and activating rho-family GTPases. Cancer Res 65(8): 3092–3099.
Terciolo C, Dobric A, Ouaissi M, Siret C, Breuzard G, Silvy F, Marchiori B, Germain S, Bonier R, Hama A, Owens R, Lombardo D, Rigot V, André F (2017) Saccharomyces boulardii CNCM I-745 restores intestinal barrier integrity by regulation of E-cadherin recycling. J Crohns Colitis 11(8): 999–1010.
Thiery JP (2009) [Epithelial-mesenchymal transitions in cancer onset and progression]. Bull Acad Natl Med 193(9): 1978–1979, discussion 1978–9.
Van Marck V, Stove C, Jacobs K, Van den Eynden G, Bracke M (2011) P-cadherin in adhesion and invasion: opposite roles in colon and bladder carcinoma. Int J Cancer 128(5): 1031–1044.
Van Marck V, Stove C, Van Den Bossche K, Stove V, Paredes J, Vander Haeghen Y, Bracke M (2005) P-cadherin promotes cell–cell adhesion and counteracts invasion in human melanoma. Cancer Res 65(19): 8774–8783.
Vieira AF, Paredes J (2015) P-cadherin and the journey to cancer metastasis. Mol Cancer 14: 178.
Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K, Quinn MC, Robertson AJ, Fadlullah MZ, Bruxner TJ, Christ AN, Harliwong I, Idrisoglu S, Manning S, Nourse C, Nourbakhsh E, Wani S, Wilson PJ, Markham E, Cloonan N, Anderson MJ, Fink JL, Holmes O, Kazakoff SH, Leonard C, Newell F, Poudel B, Song S, Taylor D, Wood S, Xu Q, Wu J, Pinese M, Cowley MJ, Lee HC, Jones MD, Nagrial AM, Humphris J, Chantrill LA, Chin V, Steinmann AM, Mawson A, Humphrey ES, Colvin EK, Chou A, Scarlett CJ, Pinho AV, Giry-Laterriere M, Rooman I, Samra JS, Kench JG, Pettitt JA, Merrett ND, Toon C, Epari K, Nguyen NQ, Barbour A, Zeps N, Jamieson NB, Graham JS, Niclou SP, Bjerkvig R, Grützmann R, Aust D, Hruban RH, Maitra A, Iacobuzio-Donahue CA, Wolfgang CL, Morgan RA, Lawlor RT, Corbo V, Bassi C, Falconi M, Zamboni G, Tortora G, Tempero MA, Gill AJ, Eshleman JR, Pilarsky C, Scarpa A, Musgrove EA, Pearson JV, Biankin AV, Grimmond SM Initiative APCG (2015) Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518(7540): 495–501.
Amit M, Yen TC, Liao CT, Binenbaum Y, Chaturvedi P, Agarwal JP, Kowalski LP, Ebrahimi A, Clark JR, Cernea CR, Brandao SJ, Kreppel M, Zöller J, Fliss D, Bachar G, Shpitzer T, Bolzoni VA, Patel PR, Jonnalagadda S, Robbins KT, Shah JP, Patel SG, Gil Z International Consortium for Outcome Research (ICOR) in Head and Neck Cancer (2013) Clinical nodal stage is a significant predictor of outcome in patients with oral cavity squamous cell carcinoma and pathologically negative neck metastases: results of the international consortium for outcome research. Ann Surg Oncol 20: 3575–35781.
Becker MT, Shores CG, Yu KK, Yarbrough WG (2004) Molecular assay to detect metastatic head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 130: 21–27.
Brierley JD, Gospodarowicz MK, Wittekind C (2009) TNM Classification of Malignant Tumours 7th edn Wiley-Blackwell: NJ, USA.
Civantos FJ, Zitsch RP, Schuller DE, Agrawal A, Smith RB, Nason R, Petruzelli G, Gourin CG, Wong RJ, Ferris RL, El Naggar A, Ridge JA, Paniello RC, Owzar K, McCall L, Chepeha DB, Yarbrough WG, Myers JN (2010) Sentinel lymph node biopsy accurately stages the regional lymph nodes for T1-T2 oral squamous cell carcinomas: results of a prospective multi-institutional trial. J Clin Oncol 28: 1395–1400.
D’Cruz AK, Vaish R, Kapre N, Dandekar M, Gupta S, Hawaldar R, Agarwal JP, Pantvaidya G, Chaukar D, Deshmukh A, Kane S, Arya S, Ghosh-Laskar S, Chaturvedi P, Pai P, Nair S, Nair D, Badwe R Head and Neck Disease Management Group (2015) Elective versus therapeutic neck dissection in node-negative oral cancer. N Engl J Med 373: 521–529.
Ferlito A, Rinaldo A, Devaney KO, Nakashiro K, Hamakawa H (2008) Detection of lymph node micrometastases in patients with squamous carcinoma of the head and neck. Eur Arch Otorhinolaryngol 265: 1147–1153.
Gould VE, Bloom KJ, Franke WW, Warren WH, Moll R (1995) Increased numbers of cytokeratin-positive interstitial reticulum cells (CIRC) in reactive, inflammatory and neoplastic lymphadenopathies: hyperplasia or induced expression? Virchows Arch 425: 617–629.
van der Gun BT, Melchers LJ, Ruiters MH, de Leij LF, McLaughlin PM, Rots MG (2010) EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis 31: 1913–1921.
Hartana CA, Kinn J, Rosenblatt R, Anania S, Alamdari F, Glise H, Sherif A, Winqvist O (2016) Detection of micrometastases by flow cytometry in sentinel lymph nodes from patients with renal tumours. Br J Cancer 115: 957–966.
Millrud CR, Kvarnhammar AM, Tajti J, Munck-Wikland E, Uddman R, Cardell LO (2013) Nod-like receptors in head and neck squamous cell carcinoma. Acta Otolaryngol 133: 1333–1344.
Psychogios G, Mantsopoulos K, Bohr C, Koch M, Zenk J, Iro H (2013) Incidence of occult cervical metastasis in head and neck carcinomas: development over time. J Surg Oncol 107: 384–387.
Rabassa ME, Croce MV, Pereyra A, Segal-Eiras A (2006) MUC1 expression and anti-MUC1 serum immune response in head and neck squamous cell carcinoma (HNSCC): a multivariate analysis. BMC Cancer 6: 253.
Rydberg C, Månsson A, Uddman R, Riesbeck K, Cardell LO (2009) Toll-like receptor agonists induce inflammation and cell death in a model of head and neck squamous cell carcinomas. Immunologyl 128(1 Suppl): e600–e611.
Tao L, Lefèvre M, Ricci S, Saintigny P, Callard P, Périé S, Lacave R, Bernaudin JF, Lacau St, Guily J (2006) Detection of occult carcinomatous diffusion in lymph nodes from head and neck squamous cell carcinoma using real-time RT-PCR detection of cytokeratin 19 mRNA. Br J Cancer 94: 1164–1169.
Triantafyllou A, Williams MD, Angelos P, Shah JP, Westra WH, Hunt JL, Devaney KO, Rinaldo A, Slootweg PJ, Gnepp DR, Silver C, Ferlito A (2016) Incidental findings of thyroid tissue in cervical lymph nodes: old controversy not yet resolved? Eur Arch Otorhinolaryngol 273: 2867–2875.
Vig N, Mackenzie IC, Biddle A (2015) Phenotypic plasticity and epithelial-to-mesenchymal transition in the behaviour and therapeutic response of oral squamous cell carcinoma. J Oral Pathol Med 44: 649–655.
Yamauchi K, Fujioka Y, Kogashiwa Y, Kohno N (2011) Quantitative expression study of four cytokeratins and p63 in squamous cell carcinoma of the tongue: suitability for sentinel node navigation surgery using one-step nucleic acid amplification. J Clin Pathol 64: 875–879.
Yanamoto S, Kawasaki G, Yoshitomi I, Iwamoto T, Hirata K, Mizuno A (2007) Clinicopathologic significance of EpCAM expression in squamous cell carcinoma of the tongue and its possibility as a potential target for tongue cancer gene therapy. Oral Oncol 43: 869–877.
Arcangeli A, Crociani O, Lastraioli E, Masi A, Pillozzi S, Becchetti A (2009) Targeting ion channels in cancer: a novel frontier in antineoplastic therapy. Curr Med Chem 16(1): 66–693.
Barmeyer C, Rahner C, Yang Y, Sigworth FJ, Binder HJ, Rajendran VM (2010) Cloning and identification of tissue-specific expression of KCNN4 splice variants in rat colon. Am J Physiol Cell Physiol 299(2): C251–C263.
Barresi V, Trovato-Salinaro A, Spampinato G, Musso N, Castorina S, Rizzarelli E, Condorelli DF (2016) Transcriptome analysis of copper homeostasis genes reveals coordinated upregulation of SLC31A1, SCO1, and COX11 in colorectal cancer. FEBS Open Bio 6(8): 794–806.
Becchetti A, Arcangeli A, Del Bene MR, Olivotto M, Wanke E (1992) Intra and extracellular surface charges near Ca2+ channels in neurons and neuroblastoma cells. Biophys J 63(4): 954–965.
Carozzi VA, Canta A, Chiorazzi A (2015) Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms? Neurosci Lett 596: 90–107.
Crociani O, Zanieri F, Pillozzi S, Lastraioli E, Stefanini M, Fiore A, Fortunato A, D’Amico M, Masselli M, De Lorenzo E, Gasparoli L, Chiu M, Bussolati O, Becchetti A, Arcangeli A (2013) hERG1 channels modulate integrin signaling to trigger angiogenesis and tumor progression in colorectal cancer. Sci Rep 3: 3308.
D’Amico M, Gasparoli L, Arcangeli A (2013) Potassium channels: novel emerging biomarkers and targets for therapy in cancer. Recent Pat Anticancer Drug Discov 8(1): 53–65.
Eil R, Vodnala SK, Clever D, Klebanoff CA, Sukumar M, Pan JH, Palmer DC, Gros A, Yamamoto TN, Patel SJ, Guittard GC, Yu Z, Carbonaro V, Okkenhaug K, Schrump DS, Linehan WM, Roychoudhuri R, Restifo NP (2016) Ionic immune suppression within the tumour microenvironment limits T cell effector function. Nature 537(7621): 539–543.
Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, Castedo M, Kroemer G (2014) Systems biology of Cisplatin resistance: past, present and future. Cell Death Dis 5(5): e1257.
Gasparoli L, D’Amico M, Masselli M, Pillozzi S, Caves R, Khuwaileh R, Tiedke W, Mugridge K, Pratesi A, Mitcheson JS, Basso G, Becchetti A, Arcangeli A (2015) New pyrimido-indole compound CD-160130 preferentially inhibits the KV11.1B isoform and produces antileukemic effects without cardiotoxicity. Mol Pharmacol 87(2): 183–196.
Huang CP, Fofana M, Chan J, Chang CJ, Howell SB (2014) Copper transporter 2 regulates intracellular copper and sensitivity to Cisplatin. Metallomics 6(3): 654–661.
Huang H, Zhu L, Reid BR, Drobny GP, Hopkins PB (1995) Solution structure of a cisplatin-induced DNA interstrand cross-link. Science 270(5243): 1842–1845.
Huang X, Jan LY (2014) Targeting potassium channels in cancer. J Cell Biol 206(2): 151–162.
Hui C, Lan Z, Yue-li L, Li-lin H, Li-lin H (2015) Knockdown of Eag1 expression by RNA interference increases chemosensitivity to Cisplatin in ovarian cancer cells. Reprod Sci 22(12): 1618–1626.
Ishida S, Lee J, Thiele DJ, Herskowitz I (2002) Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 99(22): 14298–14302.
Jentsch TJ, Lutter D, Planells-Cases R, Ullrich F, Voss FK (2016) RAC: molecular identification as LRRC8 heteromers with differential functions. Pflugers Arch 468(3): 385–393.
Kalayda GV, Wagner CH, Buss I, Reedijk J, Jaehde U (2008) Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with Cisplatin resistance in human ovarian carcinoma cells. BMC Cancer 8: 175.
Kartalou M, Essigmann JM (2001) Mechanisms of resistance to Cisplatin. Mutat Res 478: 23–43.
Katano K, Kondo A, Safaei R, Holzer A, Samimi G, Mishima M, Kuo YM, Rochdi M, Howell SB (2002) Acquisition of resistance to Cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res 62(22): 6559–6565.
Khan AJ, Wall B, Ahlawat S, Green C, Schiff D, Mehnert JM, Goydos JS, Chen S, Haffty BG (2011) Riluzole enhances ionizing radiation-induced cytotoxicity in human melanoma cells that ectopically express metabotropic glutamate receptor 1 in vitro and in vivo. Clin Cancer Res 17(7): 1807–1814.
Lang F, Hoffmann EK. Role of ion transport in control of apoptotic cell death (2012) Compr Physiol 2(3): 2037–2061.
Lastraioli E, Guasti L, Crociani O, Polvani S, Hofmann G, Witchel H, Bencini L, Calistri M, Messerini L, Scatizzi M, Moretti R, Wanke E, Olivotto M, Mugnai G, Arcangeli A (2004) herg1 gene and HERG1 protein are overexpressed in colorectal cancers and regulate cell invasion of tumor cells. Cancer Res 64(2): 606–611.
Lastraioli E, Perrone G, Sette A, Fiore A, Crociani O, Manoli S, D’Amico M, Masselli M, Iorio J, Callea M, Borzomati D, Nappo G, Bartolozzi F, Santini D, Bencini L, Farsi M, Boni L, Di Costanzo F, Schwab A, Onetti Muda A, Coppola R, Arcangeli A (2015) hERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma. Br J Cancer 112(6): 1076–1087.
Leanza L, O’Reilly P, Doyle A, Venturini E, Zoratti M, Szegezdi E, Szabo I (2014) Correlation between potassium channel expression and sensitivity to drug-induced cell death in tumor cell lines. Curr Pharm Des 20(2): 189–200.
Lee EL, Hasegawa Y, Shimizu T, Okada Y (2008) IK1 channel activity contributes to Cisplatin sensitivity of human epidermoid cancer cells. Am J Physiol Cell Physiol 294(6): C1398–C1406.
Marzo T, Pillozzi S, Hrabina O, Kasparkova J, Brabec V, Arcangeli A, Bartoli G, Severi M, Lunghi A, Totti F, Gabbiani C, Quiroga AG, Messori L (2015) cis-Pt I2(NH3)2: a reappraisal. Dalton Trans 44(33): 14896–14905.
Matsumoto S, Tanaka T, Kurokawa H, Matsuno K, Hayashida Y, Takahashi T (2007) Effect of copper and role of the copper transporters ATP7A and CTR1 in intracellular accumulation of cisplatin. Anticancer Res 27(4B): 2209–2216.
Muratori L, Petroni G, Antonuzzo L, Boni L, Iorio J, Lastraioli E, Bartoli G, Messerini L, Di Costanzo F, Arcangeli A (2016) hERG1 positivity and Glut-1 negativity identifies high-risk TNM stage I and II colorectal cancer patients, regardless of adjuvant chemotherapy. Onco Targets Ther 9: 6325–6332.
Owatari S, Akune S, Komatsu M, Ikeda R, Firth SD, Che XF, Yamamoto M, Tsujikawa K, Kitazono M, Ishizawa T, Takeuchi T, Aikou T, Mercer JF, Akiyama S, Furukawa T (2007) Copper-transporting P-type ATPase, ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer. Cancer Res 67(10): 4860–4868.
Pedersen SF, Klausen TK, Nilius B (2015) The identification of a volume-regulated anion channel: an amazing Odyssey. Acta Physiol (Oxf) 213(4): 868–881.
Pillozzi S, Brizzi MF, Bernabei PA, Bartolozzi B, Caporale R, Basile V, Boddi V, Pegoraro L, Becchetti A, Arcangeli A (2007) VEGFR-1 (FLT-1), beta1 integrin, and hERG K+ channel for a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome. Blood 110(4): 1238–1250.
Pillozzi S, Masselli M, De Lorenzo E, Accordi B, Cilia E, Crociani O, Amedei A, Veltroni M, D’Amico M, Basso G, Becchetti A, Campana D, Arcangeli A (2011) Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers. Blood 117(3): 902–914.
Pillozzi S, Masselli M, Gasparoli L, D’Amico M, Polletta L, Veltroni M, Favre C, Basso G, Becchetti A, Arcangeli A (2016) Macrolide antibiotics exert antileukemic effects by modulating the autophagic flux through inhibition of hERG1 potassium channels. Blood Cancer J 6: e423.
Planells-Cases R, Lutter D, Guyader C, Gerhards NM, Ullrich F, Elger DA, Kucukosmanoglu A, Xu G, Voss FK, Reincke SM, Stauber T, Blomen VA, Vis DJ, Wessels LF, Brummelkamp TR, Borst P, Rottenberg S, Jentsch TJ (2015) Subunit composition of VRAC channels determines substrate specificity and cellular resistance to Pt-based anti-cancer drugs. EMBO J 34(24): 2993–3008.
Poulsen KA, Andersen EC, Hansen CF, Klausen TK, Hougaard C, Lambert IH, Hoffmann EK (2010) Deregulation of apoptotic volume decrease and ionic movements in multidrug-resistant tumor cells: role of chloride channels. Am J Physiol Cell Physiol 298(1): C14–C25.
Samuel P, Pink RC, Caley DP, Currie JM, Brooks SA, Carter DR (2016) Over-expression of miR-31 or loss of KCNMA1 leads to increased cisplatin resistance in ovarian cancer cells. Tumour Biol 37(2): 2565–2573.
Sanguinetti MC, Jurkiewicz NK (1990) Two components of cardiac delayed rectifier K+ current: differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 96: 195–215.
Sankaranarayanan A, Raman G, Busch C, Schultz T, Zimin PI, Hoyer J, Köhler R, Wulff H (2009) Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure. Mol Pharmacol 75(2): 281–295.
Shimizu T, Lee EL, Ise T, Okada Y (2008) Volume-sensitive Cl(-) channel as a regulator of acquired Cisplatin resistance. Anticancer Res 28(1A): 75–83.
Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265–7279.
Speyer CL, Nassar MA, Hachem AH, Bukhsh MA, Jafry WS, Khansa RM, Gorski DH (2016) Riluzole mediates anti-tumor properties in breast cancer cells independent of metabotropic glutamate receptor-1. Breast Cancer Res Treat 157(2): 217–228.
Spitzner M, Ousingsawat J, Scheidt K, Kunzelmann K, Schreiber R (2007) Voltage-gated K+ channels support proliferation of colonic carcinoma cells. FASEB J 21(1): 35–44.
Stefani A, Spadoni F, Bernardi G (1997) Differential inhibition by riluzole, lamotrigine, and phenytoin of sodium and calcium currents in cortical neurons: implications for neuroprotective strategies. Exp Neurol 147(1): 115–122.
Syeda R, Qiu Z, Dubin AE, Murthy SE, Florendo MN, Mason DE, Mathur J, Cahalan SM, Peters EC, Montal M, Patapoutian A (2016) LRRC8 proteins form volume-regulated anion channels that sense ionic strength. Cell 164: 499–511.
Wang D, Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4: 307–320.
Wang YJ, Lin MW, Lin AA, Wu SN (2008) Riluzole-induced block of voltage-gated Na+ current and activation of BKCa channels in cultured differentiated human skeletal muscle cells. Life Sci 82(1-2): 11–20.
Wong RS (2011) Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res 30(1): 87–101.
Wulff H, Miller MJ, Hansel W, Grissmer S, Cahalan MD, Chandy KG (2000) Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCa1: a potential immunosuppressant. Proc Natl Acad Sci USA 97(14): 8151–8156.
Yip D, Le MN, Chan JL, Lee JH, Mehnert JA, Yudd A, Kempf J, Shih WJ, Chen S, Goydos JS (2009) A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma. Clin Cancer Res 15(11): 3896–3902.
Yoshida M, Khokhar AR, Siddik ZH (1994) Biochemical pharmacology of homologous alicyclic mixed amine platinum(II) complexes in sensitive and resistant tumor cell lines. Cancer Res 54: 3468–3473.
Zhang R, Tian P, Chi Q, Wang J, Wang Y, Sun L, Liu Y, Tian S, Zhang Q (2012) Human ether-à-go-go-related gene expression is essential for Cisplatin to induce apoptosis in human gastric cancer. Oncol Rep 27(2): 433–440.
There is a need for optimising our currently-available tools for radiological assessment of response in patients with NETs. This could be done by (1) maximising the information provided by current standard size-based criteria (such as RECIST), (2) incorporation of morphological assessment (e.g., Choi criteria (Faivre et al, 2012)) or by (3) incorporating metabolic techniques (nuclear medicine (Sundin and Rockall, 2012)) into response assessment. This study focused on the first approach.
This post hoc analysis is the first study to identify an alternative tumour shrinkage cut-off for definition of partial response in sunitinib-treated pNET patients. While the classical cut-off of 30% of tumour diameter reduction was shown to be too restrictive and not impacting PFS in the multivariable analysis, our proposed alternative of 10% reduction did impact PFS, even when adjusted to other prognostic factors.
Best-response to treatment was achieved early-on in the treatment with sunitinib: at a median of 3 months to best-response, with 83.9% of patients achieving the best-response during the first 7 months of treatment. Therefore, this alternative definition of objective partial response can be used as an early marker of benefit from treatment and could impact patients’ management.
Our results support that a reduction of 10% may be used as an accurate surrogate for PFS. Earlier studies have shown the importance of maintenance of dose intensity in sunitinib-treated patients in renal cell carcinoma (RCC) (Houk et al, 2010). We would therefore suggest that dose reduction rather than dose interruption is considered in the event of treatment-related toxicity for those patients who have achieved our suggested 10% reduction on the size of targeted lesions, in accordance with the prescribing information. Moreover, since, as mentioned above, the best-response was achieved early-on following initiation of treatment, we also argue that should patients not achieve a 10% of tumour shrinkage after 7 months of treatment, the dose of sunitinib could be increased to 50 mg daily (if well tolerated) as suggested in the sunitinib SPC (EMA, 2016) and as detailed in the phase III clinical trial protocol which stated that ‘in patients without an objective tumour response who had grade 1 or lower non-haematologic or grade 2 or lower haematologic treatment-related adverse events during the first 8 weeks, the dose could be increased to 50 mg per day’ (Raymond et al, 2011). Although dose escalation of sunitinib has been explored in RCC and gastrointestinal stromal tumour (GIST) (Patel, 2012; Ornstein et al, 2016; Shi et al, 2016), experience of doing so in pNET is limited; only 10% of patients treated with sunitinib in the phase III pivotal clinical trial had dose increased to 50 mg daily, and its impact is unclear (Raymond et al, 2011).
Alternative response cut-offs have also been explored in the past in other malignancies such as RCC, in which targeted therapies (including sunitinib) are a cornerstone of systemic management (Thiam et al, 2010, Krajewski et al, 2011, 2014). (Krajewski et al 2011, 2014) validated a different cut-off for RECIST criteria, able to identify more accurately those patients with benefit (in terms of overall survival) from anti-angiogenic agents (including sunitinib). In keeping with our findings, a cut-off of 10% of the sum of the longest tumour diameter shrinkage on the first follow-up CT scan was predictive of outcome, however, some challenges existed such as the lack of placebo-treated patients which did not allow them to explore whether the new cut-off was a predictive factor or not (Chen et al, 2014). The fact that similar findings have been shown in small series of gastrointestinal NETs treated with somatostatin analogues provide robustness to our findings (Luo, 2017). In this series, Luo et al included 33 patients with NETs treated with SSA; the authors identified that achieving a response of 10% reduction in target lesions impacted PFS.
Our study has some note-worthy strengths such as the fact that all data were prospectively collected as part of phase II and phase III clinical trials, in addition to the previous quality-assurance of these data for registration purposes. We also explored first which was the most informative time-point, in order to calculate the response cut-off at such time-point; this, was one of the acknowledged limitations of the previous studies in RCC (Chen et al, 2014). Although the use of morphological changes (such as Choi criteria (van der Veldt et al, 2010)) have been suggested in order to improve assessment of response to targeted therapies, the incorporation of such approaches to daily practice could be challenging due to the fact that it requires specialist radiological input for assessment of changes within density of target lesions (Faivre et al, 2012). We do therefore believe that the application of our 10% alternative cut-off could be relatively straight-forward for clinicians managing patients with pNETs in daily practice.
Limitations of our study include the fact that our analysis was limited to the measurement of marker lesions; appearance of new lesions could not be included in our analysis since it is not included in the calculation of change in percentages of response. Whether this radiological response is a predictive factor in addition to prognostic remains unclear, since patients treated with placebo who achieved such response did benefit in terms of PFS as well. It is worth highlighting the fact that the phase III study included in this analysis was interrupted early by the independent data monitoring committee (IDMC); and that following final results and demonstration of superiority of sunitinib, cross-over was allowed. Thus, the fact that some of the patients initially allocated to the placebo arm will have been treated with sunitinib (including patients in the absence of disease progression) could also explain why some patients in the placebo arm did have radiological response to treatment and its impact on prognosis regardless of the treatment group (as shown in the multivariable analysis). This would warrant further investigations in future placebo-controlled clinical trials. Another of the limitations from our study was that different sunitinib schedules were used across the phase II and the phase III studies. We do wonder whether this could be the explanation why we were unable to replicate the differences in median PFS found in the phase III study when comparing patients who did/did not reach the 10% alternative cut-off in the phase II patient population. The higher partial response rate identified in the phase II study patients could have also contributed to this. Finally, since the limited sample size did not allow us to divide our sample in separate design and validation cohorts, our results should be validated in future prospective series or clinical trials. Finally, it could also be argued that the 10% reduction in sum of marker lesions might be included within the expected inter-observer and inter-examination variability, especially when CT scans are performed as part of the daily practice and assessed outside the setting of a prospective clinical trial. It is worth highlighting that, although we do agreed with this being a possibility we do believe it is unlikely to happen due the fact that the CT scans employed in this study were not centrally reviewed and that the assessments and measurements were based on local radiologist (therefore reflecting standard clinical practice).
In conclusion, our results support that reduction of 10% in the measurement of marker lesions, impacts on PFS and should be considered enough to classify pNET patients as responders to sunitinib and likely to derive clinical benefit from treatment.
To view more documents, please visit http://www.snl.com:81/irweblinkx/docs.aspx?IID=109084.